A new study that finds long-term heat therapy may increase mitochondrial function in the muscles has been conducted by the researchers at Brigham Young University (BYU). The discovery could lead to new treatments for people with chronic illness or disease. Mitochondria, the 'energy centers' of the cells, are essential for maintaining good health. A decrease in the number or function of mitochondria may contribute to chronic and potentially serious conditions such as heart disease, chronic obstructive pulmonary disease, and type 2 diabetes (lat. Diabetes Mellitus). Exercise has been shown to create new mitochondria and improve the function of existing mitochondria.
A new product that combines two of Utah County’s favorite temptations into one has been developed by the students at developed by Brigham Young University (BYU). Sparkling Scoops, a hard-pack, carbonated ice cream created by a team of eight BYU students, has the taste of ice cream and the experience of drinking a soda. It has the consistency and creaminess and body as an ice cream you would buy at the grocery store, but the fizz, that tingle builds as you continue it. The 'sparkling' single-serve ice cream comes in 8-ounce aluminum cans with a pull-top. It’s creamy, fizzy and has a label that keeps the ice cream cold without making it cold to hold. The team developed three flavors - root beer float, orange cream, and cherry cola.
The scientific team at Stanford University has developed an innovative treatment for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS), Huntington’s Disease, and neuronal injury, such as including spinal cord injury and glaucoma, by targeting reactive astrocytes. Initial studies were performed with neutralizing antibodies. In addition, inventors, including Ben A Barres, Shane A Liddelow, and Kevin A Guttenplan, are continuing their work to identify and characterize the specific neurotoxic factor released by activated astrocytes.
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD). The company's platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Their research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.
It may be possible in the future to screen patients for Alzheimer’s disease (lat. morbus Alzheimerianus) using an eye exam. Using technology similar to what is found in many eye doctors’ offices, researchers at Washington University School of Medicine in St. Louis have detected evidence suggesting Alzheimer’s in older patients who had no symptoms of the disease. This technique has great potential to become a screening tool that helps decide who should undergo more expensive and invasive testing for Alzheimer’s disease prior to the appearance of clinical symptoms.
Scientists at the Monash University in collaboration with the Harvard University, the University of Cambridge and the University of Cincinnati have identified how the inactive or latent form of myostatin (also known as GDF8), a signaling protein responsible for limiting muscle, is activated. This discovery will help in finding a better treatment to improve muscle function in diseases such as muscular dystrophy, amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, and cancer cachexia, a muscle wasting condition. The study was funded by the Muscular Dystrophy Association, the National Institute of Health, the American Heart Association, the University of Cincinnati and Australia's National Health and Medical Research Council.